![Hematology and Oncology Research-Targeted therapies-Cesar A. Perez](https://oap-researchnetwork.org/uploads/624-EditorPhoto.jpg)
Cesar A. Perez
Address:
529 S Jackson St, Suite 426
Louisville, KY 40202
United States
Research Interests:
Targeted therapies, Malignant Hematology, Lymphomas, Multiple Myeloma, Head and Neck Cancer, Lung Cancer, Refractory Thyroid Cancer, Multi-kinase inhibitors.
Biography:
- Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent and/or metastatic squamous cell carcinoma of the head and neck. Perez CA, Song H, Raez LE, Agulnik M., Dekker A, Stenson K., Blair EA, Olopade OI, Seiwert TY, Vokes EE, Cohen EE. Oral Oncol. 2012 Apr 16. PMID: 22513208
- Overcoming the resistance to Crizotinib in patients with Non-Small Cell Lung Cancer harboring EML4/ALK translocation. Perez CA, Velez M, Raez LE, Santos ES. Lung Cancer. 2014 May;84(2):110-115. PMID: 24598368
- Hodgkin Lymphoma in Pregnancy: Achieving the Best Outcome for Both Mother and Infant. Van Driessche F, Perez CA, Clin Adv Hematol Oncol 2013. 11(8): 537-8. PMID: 24518428
- Biologic impact and clinical implication of mTOR inhibition in metastatic breast cancer. Westin GF, Perez CA, Wang E, Glück S. Int J Biol Markers. 2013 Aug 29;28(3):233-241. PMID: 23999849
- Targeting the c-Met pathway in lung Cancer. Belalcazar A; Azana D, Perez, CA; Raez LE, Santos ES. Expert Rev Anticancer Ther. 2012 Apr;12(4):519-28. PMID: 22500688